Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 73

1.

Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.

Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, Boix V, Moreno S, Barrufet P, Castaño M, Carrero A, Galindo MJ, Suárez-Lozano I, Knobel H, Raffo M, Solís J, Yllescas M, Esteban H, González-García J, Berenguer J, Imaz A; GESIDA-8314 Study Group..

PLoS One. 2017 Feb 9;12(2):e0172184. doi: 10.1371/journal.pone.0172184.

2.

Mx1, OAS1 and OAS2 polymorphisms are associated with the severity of liver disease in HIV/HCV-coinfected patients: A cross-sectional study.

García-Álvarez M, Berenguer J, Jiménez-Sousa MA, Pineda-Tenor D, Aldámiz-Echevarria T, Tejerina F, Diez C, Vázquez-Morón S, Resino S.

Sci Rep. 2017 Jan 31;7:41516. doi: 10.1038/srep41516.

3.

Are in vivo selections on the path to extinction?

Berenguer J, Mencía M, Hidalgo A.

Microb Biotechnol. 2017 Jan;10(1):46-49. doi: 10.1111/1751-7915.12490.

4.

Prognostic Value of Transient Elastography in Human Immunodeficiency Virus-Infected Patients With Chronic Hepatitis C.

Pérez-Latorre L, Rivero-Juárez A, Hontañón V, Díez C, Cuenca F, Martín-Carbonero ML, Montes ML, Bellón JM, Aldámiz-Echevarría T, Carrero A, Rivero A, González-García J, Berenguer J.

Open Forum Infect Dis. 2016 Oct 3;3(4):ofw212.

5.

Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.

Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, Boix V, Moreno S, Barrufet P, Castaño M, Carrero A, Galindo MJ, Suárez-Lozano I, Knobel H, Raffo M, Solís J, Yllescas M, Esteban H, González-García J, Berenguer J, Imaz A; GESIDA-8314 Study Group..

PLoS One. 2016 Oct 11;11(10):e0164455. doi: 10.1371/journal.pone.0164455. Erratum in: PLoS One. 2017 Feb 9;12 (2):e0172184.

6.

Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients.

Medrano LM, Rallón N, Berenguer J, Jiménez-Sousa MA, Soriano V, Aldámiz-Echevarria T, Fernández-Rodríguez A, García M, Tejerina F, Martínez I, Benito JM, Resino S.

J Transl Med. 2016 Sep 2;14:257. doi: 10.1186/s12967-016-1005-7.

7.

Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining Conditions.

Serrano-Villar S, Gutiérrez F, Miralles C, Berenguer J, Rivero A, Martínez E, Moreno S.

Open Forum Infect Dis. 2016 May 12;3(2):ofw097. doi: 10.1093/ofid/ofw097. Review.

8.

Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics.

Berenguer J, Rivero A, Jarrín I, Núñez MJ, Vivancos MJ, Crespo M, Téllez MJ, Domingo P, Iribarren JA, Artero A, Márquez M, Santos I, Moreno J, Montero M, González-García J.

Open Forum Infect Dis. 2016 Mar 11;3(2):ofw059. doi: 10.1093/ofid/ofw059.

9.

Soluble Adhesion Molecules in Patients Coinfected with HIV and HCV: A Predictor of Outcome.

Aldámiz-Echevarría T, Berenguer J, Miralles P, Jiménez-Sousa MA, Carrero A, Pineda-Tenor D, Díez C, Tejerina F, Pérez-Latorre L, Bellón JM, Resino S.

PLoS One. 2016 Feb 5;11(2):e0148537. doi: 10.1371/journal.pone.0148537.

10.

Sensing of latent EBV infection through exosomal transfer of 5'pppRNA.

Baglio SR, van Eijndhoven MA, Koppers-Lalic D, Berenguer J, Lougheed SM, Gibbs S, Léveillé N, Rinkel RN, Hopmans ES, Swaminathan S, Verkuijlen SA, Scheffer GL, van Kuppeveld FJ, de Gruijl TD, Bultink IE, Jordanova ES, Hackenberg M, Piersma SR, Knol JC, Voskuyl AE, Wurdinger T, Jiménez CR, Middeldorp JM, Pegtel DM.

Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):E587-96. doi: 10.1073/pnas.1518130113.

11.

Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.

Nilsson RJ, Karachaliou N, Berenguer J, Gimenez-Capitan A, Schellen P, Teixido C, Tannous J, Kuiper JL, Drees E, Grabowska M, van Keulen M, Heideman DA, Thunnissen E, Dingemans AM, Viteri S, Tannous BA, Drozdowskyj A, Rosell R, Smit EF, Wurdinger T.

Oncotarget. 2016 Jan 5;7(1):1066-75. doi: 10.18632/oncotarget.6279.

12.

Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.

Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses MA, Kilby JM, Lutz T, Podzamczer D, Portilla J, Roth N, Wong D, Granier C, Wynne B, Pappa K.

J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):515-9. doi: 10.1097/QAI.0000000000000790. Erratum in: J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):e33.

13.

Association between IL7R polymorphisms and severe liver disease in HIV/HCV coinfected patients: a cross-sectional study.

Guzmán-Fulgencio M, Berenguer J, Jiménez-Sousa MA, Pineda-Tenor D, Aldámiz-Echevarria T, García-Broncano P, Carrero A, García-Álvarez M, Tejerina F, Diez C, Vazquez-Morón S, Resino S.

J Transl Med. 2015 Jun 30;13:206. doi: 10.1186/s12967-015-0577-y.

15.

In Vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior.

Zomer A, Maynard C, Verweij FJ, Kamermans A, Schäfer R, Beerling E, Schiffelers RM, de Wit E, Berenguer J, Ellenbroek SI, Wurdinger T, Pegtel DM, van Rheenen J.

Cell. 2015 May 21;161(5):1046-57. doi: 10.1016/j.cell.2015.04.042.

16.

Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.

Llufriu S, Sepúlveda M, Blanco Y, Marín P, Moreno B, Berenguer J, Gabilondo I, Martínez-Heras E, Sola-Valls N, Arnaiz JA, Andreu EJ, Fernández B, Bullich S, Sánchez-Dalmau B, Graus F, Villoslada P, Saiz A.

PLoS One. 2014 Dec 1;9(12):e113936. doi: 10.1371/journal.pone.0113936.

17.

Acceptance rate of clinical study endpoints and adequacy of source documentation: experience from clinical study endpoint review in NEAT001/ANRS143.

Berenguer J, Wit F, Jansson PO, Schwimmer C, Kowalska JD, Saillard J, Diallo A, Pozniak AL, Raffi F, Grarup J.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19572. doi: 10.7448/IAS.17.4.19572.

18.

Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir/ritonavir-based therapy.

Estrada V, Monge S, Gómez-Garre D, Sobrino P, Berenguer J, Bernardino JI, Santos J, Zamora AM, Martínez E, Blanco JR.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19544. doi: 10.7448/IAS.17.4.19544.

19.

FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients.

Pineda-Tenor D, Berenguer J, Jiménez-Sousa MA, García-Alvarez M, Aldámiz-Echevarria T, Carrero A, Vázquez-Morón S, García-Broncano P, Diez C, Tejerina F, Guzmán-Fulgencio M, Resino S.

BMC Med. 2014 Nov 3;12:198. doi: 10.1186/s12916-014-0198-y.

20.

rs7903146 polymorphism at transcription factor 7 like 2 gene is associated with total cholesterol and lipoprotein profile in HIV/hepatitis C virus-coinfected patients.

Pineda-Tenor D, Berenguer J, Jiménez-Sousa MA, Carrero A, García-Álvarez M, Aldámiz-Echevarria T, García-Broncano P, Diez C, Guzmán-Fulgencio M, Fernández-Rodríguez A, Resino S.

AIDS Res Hum Retroviruses. 2015 Mar;31(3):326-34. doi: 10.1089/aid.2014.0195.

Supplemental Content

Loading ...
Support Center